TBPMQ

Tetra Bio-Pharma Inc.

OTC Markets OTCPKUSDEQUITY DELAYED

0.00

■ 0.00 (0.00%)

MARKET · —

Price

Open

—

Prev close

0.00

Day high

—

Day low

—

Volume

850

Market cap

—

P/E (TTM)

—

52W range

— – 0.00

Options chain

Account required

ExpirySpot 0.00

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Trailing performance

Price return · vs SPY

Returnvs SPY

0.00% +1.4%

0.00% -3.7%

0.00% -3.1%

0.00% -11.1%

YTD

0.00% -12.3%

0.00% -20.0%

-81.82% -156.0%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Financial statements

As reported · 1 year

Blank means not reported, not zero

Line item	2021	YoY
Total revenue	$0
Operating revenue	$0
Research & development	$11.94M
Selling, general & admin	$12.25M
Total operating expense	$24.30M
Operating income	-$24.30M
Net interest income	-$1.79M
Pre-tax income	-$52.18M
Net income	-$52.18M
Net income to common	-$52.18M
Basic EPS	-0.12
Diluted EPS	-0.12
EBIT	-$50.28M
EBITDA	-$50.17M
Basic shares	445.70M
Diluted shares	445.70M

Line item

2021

YoY

Total revenue

Operating revenue

Research & development

$11.94M

Selling, general & admin

$12.25M

Total operating expense

$24.30M

Operating income

-$24.30M

Net interest income

-$1.79M

Pre-tax income

-$52.18M

Net income

-$52.18M

Net income to common

-$52.18M

Basic EPS

-0.12

Diluted EPS

-0.12

EBIT

-$50.28M

EBITDA

-$50.17M

Basic shares

445.70M

Diluted shares

445.70M

Line item	2021	YoY
Cash & equivalents	$4.89M
Cash & short-term investments	$4.89M
Total current assets	$5.95M
Property, plant & equipment	$692.25K
Total assets	$7.55M
Total current liabilities	$7.30M
Current debt	$3.11M
Total debt	$3.11M
Total liabilities	$7.30M
Retained earnings	-$126.74M
Shareholder equity	$249.33K
Working capital	-$1.35M
Net tangible assets	$249.33K
Shares issued	401.67M

Line item

2021

YoY

Cash & equivalents

$4.89M

Cash & short-term investments

$4.89M

Total current assets

$5.95M

Property, plant & equipment

$692.25K

Total assets

$7.55M

Total current liabilities

$7.30M

Current debt

$3.11M

Total debt

$3.11M

Total liabilities

$7.30M

Retained earnings

-$126.74M

Shareholder equity

$249.33K

Working capital

-$1.35M

Net tangible assets

$249.33K

Shares issued

401.67M

Line item	2021	YoY
Net income	-$52.18M
Depreciation & amortisation	$111.95K
Stock-based compensation	$1.05M
Change in working capital	-$542.73K
Operating cash flow	-$25.28M
Capital expenditure	-$1.15M
Investing cash flow	-$2.12M
Financing cash flow	$29.78M
Free cash flow	-$26.43M
End cash position	$4.89M

Line item

2021

YoY

Net income

-$52.18M

Depreciation & amortisation

$111.95K

Stock-based compensation

$1.05M

Change in working capital

-$542.73K

Operating cash flow

-$25.28M

Capital expenditure

-$1.15M

Investing cash flow

-$2.12M

Financing cash flow

$29.78M

Free cash flow

-$26.43M

End cash position

$4.89M

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

0.00

+0.00% from price

SMA 20

0.00

0.00% from price

SMA 50

0.00

0.00% from price

SMA 100

0.00

+0.00% from price

SMA 200

0.00

0.00% from price

EMA 12

0.00

+0.00% from price

EMA 26

0.00

+0.00% from price

EMA 50

0.00

+0.00% from price

RSI (14)

42.6

Neutral

MACD (12,26,9)

-0.00

Hist 0.00

ATR (14)

0.00

—

Realised vol 30D

0.0%

Annualised

Bollinger upper

0.00

20, 2σ

Bollinger lower

0.00

20, 2σ

50 / 200 cross

Death

0.00 vs 0.00

Trend bias

Below 200

0.00%

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.00

Less volatile than market

Correlation to SPY

—

Realised vol 30D

0.0%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

0.0%

Peak to trough

Max drawdown 5Y

-100.0%

Peak to trough

ATR 14

0.00

Average true range

Beta (reported)

—

5Y monthly, from filing

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.